- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00160667
A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)
An Exploratory, Double Blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study, for the Assessment of Efficacy, Safety and Tolerability of Ucb 34714 50 mg Oral Capsules in b.i.d. Administration at the Doses of 200 mg/Day and 400 mg/Day, in Subjects (at Least 18 Years Old) Suffering From Post Herpetic Neuralgia (PHN)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brussels, Belgium
-
Eeklo, Belgium
-
Genk, Belgium
-
Liege, Belgium
-
Lubbeek (Pellenberg), Belgium
-
-
-
-
-
Pleven, Bulgaria
-
Sofia, Bulgaria
-
Varna, Bulgaria
-
-
-
-
-
Hradec Kralove, Czechia
-
Prague, Czechia
-
Svitavy, Czechia
-
Usti nad Labem, Czechia
-
-
-
-
-
Annecy, France
-
Clermont-Ferrand Cedex, France
-
Nice Cedex 1, France
-
Toulouse, France
-
Voiron, France
-
-
-
-
-
Bad Worishofen, Germany
-
Bochum, Germany
-
Essen, Germany
-
Kassel, Germany
-
Rodgau, Germany
-
-
-
-
-
Gdansk, Poland
-
Grudziadz, Poland
-
Katowice, Poland
-
Kielce, Poland
-
Krakow, Poland
-
Lublin, Poland
-
Olsztyn, Poland
-
Poznan, Poland
-
Warszawa, Poland
-
Wroclaw, Poland
-
Zgierz, Poland
-
-
-
-
-
Belgarde, Serbia
-
Belgrade, Serbia
-
Kragujevac, Serbia
-
-
-
-
-
Bratislava, Slovakia
-
Dubnica nad Vahom, Slovakia
-
Kosice, Slovakia
-
Nitra, Slovakia
-
-
-
-
-
Cadiz, Spain
-
Granada, Spain
-
Hospitalet de Llobregat (Barcelona), Spain
-
Madrid, Spain
-
Sant Cugat Del Valles (Barcelona), Spain
-
Valencia, Spain
-
-
-
-
-
Bath, United Kingdom
-
Glasgow, United Kingdom
-
London, United Kingdom
-
Winchester, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Inclusion Criteria:
- Male/female subject aged 18 years or older.
- Pain present for at least 6 months after healing of the acute herpes zoster skin rash.
- Pain intensity score assessed on an 11-point numerical pain rating scale with a score of at least 4 at the screening visit and with an average weekly score of at least 4 on an 11-point numerical pain rating scale during baseline period.
Exclusion Criteria:
- Subject getting any kind of psychological support to help cope with pain such as biofeedback or behavioral cognitive therapy.
- Subject who had undergone or who is scheduled for neurolytic or neurosurgical therapy for post-herpetic neuralgia (PHN) or who receives trans-electrical neural stimulation (TENS.
- Tricyclic antidepressants (TCAs) or non-steroidal anti-inflammatory drug (NSAIDs) or permitted opioid analgesics ('strong' opioids are forbidden) that started less than 30 days and/or are not stabilized prior to screening and/or are not expected to be kept stable during the study.
- Intake of more than two pain treatments at trial entry (screening visit) including Tricyclic antidepressants (TCAs), non-steroidal anti-inflammatory drugs (NSAIDs) or permitted opioid analgesics.
- Subject being treated with Carbamazepine for any indication.
- Known coexistent source of painful peripheral neuropathy or other systemic disease associated with a secondary painful neuropathy.
- Subject being treated in the four weeks prior to screening visit with 'strong' opioid analgesics.
Exclusion Criteria:
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo tablets administered twice a day.
|
Daily oral dose of two equal intakes.
|
Experimental: Brivaracetam 200 mg/day
Brivaracetam 200 mg/day (100 mg administered twice a day).
|
Daily oral dose of two equal intakes.
Other Names:
|
Experimental: Brivaracetam 400 mg/day
Brivaracetam 400 mg/day (200 mg administered twice a day).
|
Daily oral dose of two equal intakes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage Change in Average Pain Intensity Score From Baseline to the Last Week of the 4-week Treatment Period
Time Frame: Baseline, last week of the 4-week Treatment Period
|
Pain intensity was scored on a 11-point numeric pain rating scale, ranging from 0 to 10 where 0= no pain and 10= worst possible pain. A negative value in percent change from Baseline indicates a decrease in average pain intensity score from Baseline. |
Baseline, last week of the 4-week Treatment Period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Responder Rate in Average Pain Intensity Score at the Last Week of the Treatment Period Compared to the Baseline Period
Time Frame: Baseline, last week of the 4-week Treatment Period
|
A responder is defined as a subject with a >= 30 % reduction in average pain intensity score at the Evaluation Week (last week of the Treatment Period) compared to the Baseline Period.
|
Baseline, last week of the 4-week Treatment Period
|
Percent Change From the Baseline Period to Each Weekly Mean in the Pain Intensity Score
Time Frame: Baseline, each Evaluation visit (up to Week 4)
|
Pain intensity was scored on a 11-point numeric pain rating scale, ranging from 0 to 10 where 0= no pain and 10= worst possible pain. A negative value in percent change from Baseline indicates a decrease in average pain intensity score from Baseline. |
Baseline, each Evaluation visit (up to Week 4)
|
Percent Change From the Baseline Period to the Last Week of the Treatment Period in the Sleep Interference Score
Time Frame: Baseline, last assessment during the 4-week Treatment Period
|
Sleep interference was scored on a 11-point numerical sleep interference rating scale, ranging from 0 to 10 where 0 = 'pain does not interfere with sleep', 10 = 'pain completely interferes with sleep'. A negative value in percent change from Baseline indicates a decrease in average sleep interference score from Baseline. |
Baseline, last assessment during the 4-week Treatment Period
|
Percent Change From the Baseline Period to Each Weekly Mean of the Treatment Period in the Sleep Interference Score
Time Frame: Baseline, each Evaluation visit (up to Week 4)
|
Sleep interference was scored on a 11-point numerical sleep interference rating scale, ranging from 0 to 10 where 0 = 'pain does not interfere with sleep', 10 = 'pain completely interferes with sleep'. A negative value in percent change from Baseline indicates a decrease in average sleep interference score from Baseline. |
Baseline, each Evaluation visit (up to Week 4)
|
Absolute Change From the Randomization Visit to the Evaluation / Early Discontinuation Visit in the Total Pain Score of the Short-Form McGill Pain Questionnaire (SF-MPQ)
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
The SF-MPQ has three components: the first one consists of 15 subscales (descriptors: 11 sensory, 4 affective) which are rated on an intensity scale with 0 = none, 1 = mild, 2 = moderate or 3 = severe.
Three pain scores are derived from the sum of the intensity rank values of the words chosen for sensory, affective and total subscales (descriptors).
The SF-MPQ also includes a Present Pain Intensity (PPI) index and a visual analogue scale (VAS).
Each of the 15 subscales is rated from 0=none to 3=severe pain.
The Total Pain Score of the SF-MPQ is the sum of all 15 ratings and can hence vary from 0 (15*0=0: no pain) to 60 (15*4=60: severe pain).
The mean change in total score is reported.
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Absolute Change From the Randomization Visit to the Evaluation / Early Discontinuation Visit in the Sensory Score of the Short-Form McGill Pain Questionnaire (SF-MPQ)
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. The sensory score ranges from 0 to 33. Change = observation mean at Evaluation / Early Discontinuation visit minus Randomization mean. A negative value in absolute change indicates an improvement. |
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Absolute Change From the Randomization Visit to the Evaluation / Early Discontinuation Visit in the Affective Score of the Short-Form McGill Pain Questionnaire (SF-MPQ)
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
The main component of the SF-MPQ consists of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale as 0 = none, 1 = mild, 2 = moderate or 3 = severe. The affective score ranges from 0 to 12. Change = observation mean at Evaluation / Early Discontinuation visit minus Randomization mean. A negative value in absolute change indicates an improvement. |
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Absolute Change From the Randomization Visit to the Evaluation / Early Discontinuation Visit in the Present Pain Intensity (PPI) Score of the SF-MPQ
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Present pain intensity (PPI) was rated by the subject.
The score ranges from 0 (no pain) to 5 (excruciating).
A negative value in absolute change indicates an improvement in PPI.
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Absolute Change From the Randomization Visit to the Evaluation / Early Discontinuation Visit in the Visual Analog Scale (VAS) of the SF-MPQ
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Pain burden was rated by the subject using the visual analog scale (VAS) ranging from 0 (no pain) to 100 (worst possible pain).
A negative value in absolute change indicates an improvement in pain burden.
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Percentage of Subjects With Categorized Change in Pain Assessed by Patient's Global Evaluation Scale at the Evaluation / Early Discontinuation Visit
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Patient´s global assessment of change in pain was performed using a seven-point scale (7= Marked improvement, 6= Moderate improvement, 5= Slight improvement, 4= No change, 3= Slight worsening, 2= Moderate worsening, 1= Marked worsening).
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Percentage of Subjects With Categorized Change in Post-herpetic Neuralgia Assessed by Investigator's Global Evaluation Scale at the Evaluation / Early Discontinuation Visit
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Investigator´s global assessment of change was performed using a seven-point scale (7= Marked improvement, 6= Moderate improvement, 5= Slight improvement, 4= No change, 3= Slight worsening, 2= Moderate worsening, 1= Marked worsening).
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Percent Change From Randomization Visit to the Evaluation / Early Discontinuation in the Brush-evoked Allodynia Intensity Rated by the Patient
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Brush-evoked allodynia intensity was assessed by the subject on an 11-point numerical rating scale, ranging from 0= no pain to 10= unbearable Pain. A negative value in percent change indicates an improvement in brush-evoked allodynia intensity. |
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Percent Change From Randomization Visit to the Evaluation / Early Discontinuation in the Brush-evoked Allodynia Area Measured by the Investigator
Time Frame: Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Allodynia is pain due to a normally non-painful stimulus.
The brush-evoked allodynia areas were assessed by the Investigator (location and contour of the allodynic regions drawn on a standard dermatomal map).
Areas (mm²) of the allodynic regions drawn by the Investigator were afterwards computed by means of appropriate tools and calibrated templates.
The larger the area in square centimeters the more allodynia.
A negative value in percent change in the brush-evoked allodynia area indicates improvement.
|
Randomization visit, Evaluation / Early Discontinuation visit (up to Week 4)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N01162
- 2004-000975-32 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuralgia, Postherpetic
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia ( PHN )China
-
Yonsei UniversityWithdrawnThe Evaluation of Erector Spinae Plane Block for the Pain Control of Thoracic Postherpetic NeuralgiaThoracic Postherpetic NeuralgiaKorea, Republic of
-
Bial - Portela C S.A.Completed
-
Shanghai SIMR Biotechnology Co., Ltd.CompletedPostherpetic NeuralgiaChina, Australia
-
Haisco Pharmaceutical Group Co., Ltd.CompletedPostherpetic NeuralgiaChina
-
Cairo UniversityCompleted
-
Korea University Guro HospitalUnknownNeuralgia,PostherpeticKorea, Republic of
-
Second Affiliated Hospital, School of Medicine,...CompletedPostherpetic NeuralgiaChina
-
Cubist Pharmaceuticals LLCPfizerTerminatedPostherpetic NeuralgiaUnited States
-
PfizerTerminatedPostherpetic NeuralgiaUnited States, Germany, Austria, South Africa
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States